Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triprilumab + GP for Intrahepatic Cholangiocarcinoma
NCT04413734Phase 2Unknown
- Sponsor
- Zhejiang University
- Start
- Apr 2020
- Primary completion
- Apr 2022
- Modality
- Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of triprilumab in intrahepatic cholangiocarcinoma (ICC), sponsored by Zhejiang University. Status: unknown.
02
Drugs
triprilumab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT04413734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04413734.